The present invention is related to a lipid content of a cell and its use in determination of functional quality of the cell or a cell population thereof. In particular, the invention describes lipid contents in stem cells that can be used to evaluate the functional quality, such as age, immuno-modulatory and/or angiogenic and/or osteogenic potency, of the cell population in a therapeutic cell preparation. The invention further relates to a method of detecting relative amounts of lipids and/or lipid ratios for determination of functional quality of a cell or a population thereof.
The present invention is directed to a method for the isolation of a cell population from a sample of human umbilical cord blood comprising steps of contacting said sample with an antibody binding to core-2 type O-glycan, with a sialyl Lewis x (s Lex) and Neu5Acα2- 3Galβ1-3(Neu5Acα2-3Galβ1-4Glc NAcβ1-6)Gal NAcα epitopes, such as CHO-131, and isolating the cells bound to said antibody. The invention also provides compositions comprising human cells isolated from umbilical cord blood.
The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.
The present invention relates to use of the non- secretor/secretor blood group status of an individual as a criterion for need of Lactobacillus/LAB-enriched probiotic supplementation.The present invention relates also to method of assessing the need of an individual for Lacto-bacillus/LAB-enriched probiotic supplementation by determining the secretory blood group status of the individual.
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
An in-vitro solution for simulating the growth of microbes in the presence of mammalian cells is disclosed. A layer of mammalian cells is held in a cell culture well (W1)in the presence of growth medium. A circulation unit (U1)is configured to circulate,at least a part of growth medium and microbes discarded via outlet means (O1-1) from the cell culture well (W1), back to the cell culture well (W1) via inlet means (I1-1), such that a part of the discarded growth medium is replaced with fresh growth medium. A control unit (E1)is configured to control the operation of the circulation unit (U1) based on a pH measurement carried out in the growth medium, such that the conditions in the cell culture well (W1) are kept non-toxic to the mammalian cells.
The present invention relates to a method for inducing changes in the proteome of microbes by culturing them in the presence of an animal cell. The invention further relates to a method to induce functional changes in the properties of microbes by culturing them in the presence of an animal cell. The invention further relates to the method for production of microbial proteins induced by culturing microbes in the presence of an animalcell.In addition, the present invention relates to use of an animal cells in inducing changes in the proteome of a microbe, in inducing functional changes in the properties of a microbe and in producing microbial proteins.
METHOD FOR ISOLATING CD34+ HEMATOPOIETIC STEM CELLS, NATURAL KILLER CELLS AND REGULATORY T LYMPHOCYTES FROM A SAMPLE OF HUMAN UMBILICAL CORD BLOOD BY USING AN ANTI-GD3 ANTIBODY, AS WELL AS COMPOSITIONS THEREOF
The present invention is directed to a method for the isolation of a cell population from a sample of human umbilical cord blood comprising steps of contacting said sample with an antibody binding to di-sialic acid containing saccharide epitope Neu5Ac-alpha-2-8Neu5Ac- alpha-2-3Gal, such as S2-566, and isolating the cells bound to said antibody. The invention also provides compositions comprising human cells isolated from umbilical cord blood.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to use of the ABO blood group genotype of an individual as a criterion for microbiota modulation that is tailored based on the differences in the spectrum of bacteria found between individuals with different ABO blood group genotypes. The present invention relates further to a microbial composition tailored based on the microbial genotypes shown to be specific for A, B, and/or O blood groups.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention relates also to a use of the combination to alter the relative amounts of blood cells and/or the types of blood cells in a subject. Further, the present invention relates to a use of the combination to mobilize stem cells to the bloodstream of a subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.
The present invention relates to a stem cell and/or a population thereof having a specific profile of cell surface proteins and/or proteoglycans. The present invention also relates to use of a proteolytic enzyme in the modification of the cell surface of a stem cell. The present invention further relates to a method of modifying the cell surface of a stem cell by treatment with a proteolytic enzyme.
The present invention relates to methods utilizing novel target genes related to differentiation status of human stem cells. In particular, the present invention provides a method of detecting the differentiation status of a human stem cell population comprising a step of preparing from a sample of the stem cells a gene expression profile based on the expression level of at least one of glycosyltransferase genes B3GNT5, GALNT1 and GALNT7. The invention also relates to method for identifying compounds capable of modulating or hindering differentiation of human stem cells.
The present invention relates to a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. The present invention further relates to a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype.
The present invention relates to a probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with non-secretor blood group phenotype. The present invention further relates to a method of tailoring a probiotic composition based on the bifidobacteria found from the intestine of at least one non-secretor individual.
METHOD OF DISTINGUISHING UNDIFFERENTIATED MESENCHYMAL STEM CELLS AND DIFFERENTIATED MESENCHYMAL STEM CELLS FROM EACH OTHER BY USING AN ANTIBODY AGAINST THE BLOOD GROUP I ANTIGEN
The present invention relates to a method of distinguishing and/or screening mesenchymal stem cells using an antibody against the blood group i antigen. The present invention also relates to a use of an antibody against the blood group i antigen in distinguishing mesenchymal stem cells. The present invention also relates to a use of an antibody against the blood group i antigen in screening of mesenchymal stem cells. Further, the present invention relates to a cell population screened with an antibody against the blood group i antigen.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
The present invention relates to an in vitro and/or ex vivo method of screening probiotic bacterial strains. The present invention also relates to a method of assessing quality of probiotic culture. In addition, the present invention relates to use of animal cells in screening of a probiotic strain. The present invention also relates to use of animal cells in assessing quality of probiotic culture.
The present invention relates to a method of characterizing and/or identifying cell surface molecular composition in a cell and its use in analysis of the cell status. The present invention relates also to a method of forming a cell surface protein, peptide, glycan or glycopeptide profile and their use in analysis of the cell status. Further, the present invention relates to a platform for analyzing cell surface protein, peptide, glycan or glycopeptide composition in a cell and its use in analysis of the cell status. The invention relates also to the use of a cell surface protein composition as a glycoproteomic data handling tool.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
17.
AN ANTIBODY-GLYCAN COMPLEX TARGETING THE DISIALYL CORE II AND SIALYL LEWIS X STRUCTURES, AND USES THEREOF INVOLVING ANALYSIS OF STEM CELLS OR CANCER CELLS
The present invention revealed novel antibody-saccharide-complexes and methods and uses related to analysis of cells. The present invention is further related to a method of selection of new antibody with CHO-specificity and to a use of antibodies produced for the analysis of stem cells or cancer cells or other cells or tissues known to bind to CHO-antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12P 19/44 - Preparation of O-glycosides, e.g. glucosides
18.
ANTIBODIES DIRECTED TO TRA ANTIGENS, AND METHODS OF PRODUCTION, SCREENING AND ANALYSIS OF SAID ANTIBODIES, AS WELL AS METHODS OF ANALYSIS OF STEM CELLS AND CANCER CELL
The present invention provides a complex of Tra-antibody bound to an isolated glycan comprising type I- N-acetyllactosamine comprising target structure. The invention is also directed to methods and uses utilizing said complex.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a method of protecting stem cells in a clinical graft against the destruction induced by the complement system by adding to the graft at least one factor capable of inhibiting the complement. The present invention relates also to the use of a factor capable of inhibiting the complement to protect stem cells in a clinical graft against the destruction induced by the complement system.
The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
The invention describes novel reagents that can be applied for analysis of the quality of human cells. The method evaluates the integrity of the plasma membrane of the cells by detecting novel glyco structures found only intracellularly. The method can be applied, for example, to demonstrate exposure of therapeutic cell preparation to potentially harmful conditions. It can also be used as a quality control tool in methods in which intact cell membrane is essential and it can be applied in separation of damaged cells from non- damaged.
The invention relates to a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) cells on a lectin. The invention relates also to the use of a lectin in a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) celts and a culture medium composition containing a lectin attached on the culturing plates.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
23.
HUMAN MONOCLONAL ANTIBODIES DIRECTED TO SIALYL LEWIS C, SIALYL TN AND N-GLYCOLYLNEURAMINIC ACID EPITOPES AND A METHOD OF ANALYSIS OF STEM CELLS COMPRISING SAID EPITOPES
This invention relates to antibody engineering technology. More particularly, the present invention relates to human IgM antibodies and derivatives thereof, which have novel binding specificity with regard to several oligosaccharide sequences and/or xenoantigenic sialic aicd residue. The present invention also relates to processes for making and engineering such novel saccharide and/or NeuGc-binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics, enabling qualitative and quantitative determination of xenoantigenic NeuGc in biological and raw material samples, as well as in immunotherapy, enabling blocking of xenoantigenic NeuGc in patients.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G01N 33/532 - Production of labelled immunochemicals
The invention is directed to the analysis of novel acidic glycan markers of several types of human cells. The analysis is performed by mass spectrometry or specific binder molecules.
The invention describes reagents and methods for speficic binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.
The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by changing sialylation and/or fucosylation levels of the cells. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered. The control methods are preferably mass spectrometric methods.
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
The present invention provides methods and mate rials to modulate and grow stem cells by contacting stem cells with a binder recognizing te rminal glycan structures of stem cells. The modulation can be morphological change, change in differentiation status, biological status or adherence. The materials provided in the present invention are also useful to screen such a binding agents and binders.
The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.
The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.
The invention describes novel compositions of glycans, glycomes, from human embryonic stem cells, and especially novel subcompositions of the glycomes with specific monosaccharide compositions and glycan structures. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore, the invention is directed to stem cells carrying the modified glycomes on their surfaces. The glycomes are preferably analysed by profiling methods able to detect reproducibly and quantitatively numerous individual glycan structures at the same time. The most preferred type of the profile is a mass spectrometric profile. The invention specifically revealed novel target structures and is especially directed to the development of reagents recognizing the structures.
The present invention discloses a method of evaluating the status of a stem cell preparation comprising the step of detecting the presence of a glycan structure or a group of glycan structures in said preparation. The detection step can be performed by the use of a lectin specific to a glycan structure of interest.
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
patents